Stocklytics Platform
Asset logo for symbol CPRX
Catalyst Pharmaceuticals
CPRX92
$22.55arrow_drop_up0.17%$0.03
High Quality
High Growth
Asset logo for symbol CPRX
CPRX92

$22.55

arrow_drop_up0.17%

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

Catalyst Pharmaceuticals (CPRX) Stocklytics Forecast

Catalyst Pharmaceuticals Inc (CPRX) is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for rare neurological diseases. The company's stock price has been subject to much speculation and prediction in recent years. Many analysts and investors are interested in predicting the future performance of CPRX stock in order to make informed investment decisions.
Looking ahead, there are several factors that could potentially impact the stock price of Catalyst Pharmaceuticals Inc. One important factor is the company's pipeline of drugs under development. Catalyst Pharmaceuticals has a number of promising drug candidates in its pipeline, including Firdapse and CPP-115, which have shown positive results in clinical trials. If these drugs receive regulatory approval and successfully reach the market, it could have a significant positive impact on the company's stock price.
add Catalyst Pharmaceuticals to watchlist

Keep an eye on Catalyst Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for Catalyst Pharmaceuticals (CPRX) stock?

Analysts have set a target price of $24.3 for Catalyst Pharmaceuticals (CPRX), based on forecasts from 28 analysts. The predicted price range extends from a high of $34 to a low of $7. This represents a potential increase of up to 50.78% and a decrease of -68.96% from the current price of $22.55. These forecasts are as of 2020 Aug 12.
help

What are the analyst ratings for Catalyst Pharmaceuticals (CPRX) stock?

The analyst ratings for Catalyst Pharmaceuticals (CPRX) are distributed as follows: 8 analysts recommend buying, 0 have a neutral stance, and 0 suggest selling. There is a split consensus, with equal support for two of the rating categories. These ratings indicate the general sentiment among the analysts covering Catalyst Pharmaceuticals .
help

What is the AI price prediction for Catalyst Pharmaceuticals (CPRX) stock?

At present, there is no AI or machine-learning-based price prediction available for Catalyst Pharmaceuticals (CPRX) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level